Antimicrobial restrictions

Antimicrobial formulary

The Queensland Children’s Hospital (QCH) antimicrobial formulary is a core component of the Antimicrobial stewardship program.

It is the responsibility of the prescriber to obtain appropriate AMS code for restricted antimicrobials.

  • Dr Julia Clark
  • Dr Clare Nourse
  • Dr Sophie Wen
  • Dr Adam Irwin
  • Dr Vikram Vaska
  • Dr Angela Berkhout
  • QCH ID Fellow (only for LAM listed items – use outside the LAM requires an IPA signed off by an ID SMO)
The QCH Antimicrobial formulary should be used in conjunction with the current Queensland Health List of Approved Medicines (LAM).

All other antimicrobials not listed or used for off label/ off license indications, require a CGOV Individual patient approval request submitted by the Treating Clinician and authorised by a Paediatric Infection Specialist prior to prescribing, supply or use.

Specific clinical scenarios involving antimicrobials that require authorisation by a Paediatric Infection Specialist, are listed in the CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au).

For more information about Antimicrobial supply at QCH, please refer to CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au) for guidance.

The QCH Antimicrobial formulary is divided into the following three categories:

Unrestricted (green)

Unrestricted (green)Green Antimicrobials can be prescribed for a clinically appropriate indication and duration by all prescribers as per LAM criteria. Document the indication, dose and duration with each prescription/ order.

Restricted (amber)

Restricted (amber)Amber Antimicrobials can be prescribed for listed indications for specific time frame. However, approval is required for use outside these indications (and time frames).

Where use is outside these criteria, an AMS code is required, the Prescriber will contact the Paediatric Infection Specialist or ID Fellow on service who will consider the antimicrobial’s use and duration of therapy.

Please document:

  • The indication
  • Intended dose and duration of therapy or review date
  • The unique AMS Code and the name of the authorising Paediatric Infection specialist must be added to the antimicrobial order/prescription and the ieMR clinical note.

For SAS antimicrobials, the prescriber must also complete the following electronic approval requests to pharmacy and infectious diseases consultant on service:

Reserved (red)

Reserved (red)Red Antimicrobials may only be prescribed for following authorisation by Paediatric Infection Specialist or ID Fellow on service through provision of a unique AMS Code.

Please document:

  • The indication
  • Intended dose and duration of therapy or review date
  • The unique AMS Code must be added to the antimicrobial order/prescription and the name of the authorising Paediatric Infection specialist to the ieMR clinical note.

For SAS antimicrobials, the prescriber must also complete the following electronic approval requests to pharmacy and infectious diseases consultant on service:

For more information about Antimicrobial supply at QCH, please refer to CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au)

Search QCH Antimicrobial formulary (generic name)

AntibioticColour code

Amoxicillin (oral/IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Amoxicillin / Clavulanic acid (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Amphotericin B lozenges (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Benzathine penicillin (IM)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Benzylpenicillin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Cefaclor (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Cefalexin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Cefazolin (IV) (inpatient)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Chloramphenicol eyedrops (topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Clotrimazole (topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Dicloxacillin (IV/oral)


Product discontinued January 2022. Approval required for all indications.



Red

Flucloxacillin (IV/oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Framycetin - Gramicidin - Dexamethasone (Sofradex / Otodex) Ear drops


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Metronidazole (oral/IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:




Green

Miconazole (topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Nitrofurantoin (oral capsules)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Nystatin (oral/ topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Permethrin (topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines



Green

Phenoxymethylpenicillin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Pyrantel (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Roxithromycin (150mg oral tablets)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Tinidazole (oral) (SAS)


Approval required:



Green

Trimethoprim (oral tablets)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Trimethoprim / Sulfamethoxazole (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Green

Aciclovir (eye ointment)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Upon advice of Ophthalmologist



Amber

Aciclovir (topical cream)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Upon advice of Haematologist/Oncologist



Amber

Aciclovir (IV/oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. IV Aciclovir not suitable for IDT or SPT due to alkaline pH

  • Herpes simplex encephalitis (IV only - 72 hours)

  • Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours)

  • Disseminated herpes zoster in immunocompromised patients (72 hours)

  • Varicella zoster encephalitis or pneumonia in all patients (IV only - 72 hours)

  • Ophthalmic herpes zoster (72 hours)



Amber

Albendazole (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:




Amber

Amoxicillin/Clavulanate (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Amoxicillin, Clarithromycin and Esomeprazole (Triple therapy)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Eradication of proven Helicobacter pylori for 7 to 14 days under care of a Gastroenterologist according to the Australian Therapeutic guidelines (Antibiotics).



Amber

Liposomal Amphotericin B (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Azithromycin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Azithromycin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Cefazolin (with preservative) eyedrops


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Upon advice from Ophthalmology for Acute management of Open Globe Injuries, keratitis, endophthalmitis (health.qld.gov.au)



Amber

Cefazolin (IV) (HITH)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Cefepime (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Cefotaxime (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Cefoxitin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Ceftazidime (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Ceftazidime intravitreal injection


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Upon advice from Ophthalmology for Acute management of Open Globe Injuries  (health.qld.gov.au) (1 dose)



Amber

Ceftriaxone (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



Amber

Ceftriaxone (IV) (HITH)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Cefuroxime (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



Amber

Chloramphenicol eye ointment


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


For Ophthalmic use only



Amber

Cephazolin (Cefazolin) Intravitreal and intracameral injection


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Upon advice from Ophthalmology for Acute management of Open Globe Injuries  (health.qld.gov.au) (1 dose)



Amber

Ciprofloxacin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



Amber

Ciprofloxacin eardrops


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



Amber

Ciprofloxacin/ Hydrocortisone (Ciproxin HC) eardrops


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:




Amber

Clindamycin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • In neonates only, for approved indications (sepsis with nmMRSA risk factors) (48 hours)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Clindamycin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Colistin (inhaled)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Cystic fibrosis - according to eligibility criteria in guideline



Amber

Dapsone (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Second line agent for PJP prophylaxis in oncology/haematology patients

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Doxycycline (IV – SAS)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


For single dose - use by Physicians trained in interventional radiology and with proper skills in sclerotherapy – for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients.(SAS approval required)



Amber

Doxycycline (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Acne (adolescents) (3 months under guidance of Dermatologist).



Water immersed wound infection according to guideline criteria (Children over 8 years of age) (24 hours)



Amber

Erythromycin (IV, oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved:


Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Famciclovir (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.

  • Herpes zoster in immunocompetent patients (72 hours)

  • Herpes zoster in immunocompromised patients (72 hours)

  • Ophthalmic herpes zoster (72 hours)



Amber

Fluconazole (IV/ oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Gentamicin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Gentamicin eye drops


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Use upon advice from Ophthalmology team



Amber

Griseofulvin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • For use in recalcitrant laboratory proven tinea infection according to the Australian Therapeutic guidelines (Antibiotic)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Hydroxychloroquine (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


For use according to the QH LAM by an authorised prescriber in accordance with the Medicines and Poisons (Medicines) Regulation 2021.



Amber

Itraconazole (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Lincomycin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Mebendazole (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:




Amber

Minocycline (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Acne (adolescents) upon advice from Dermatologist (up to 3 months)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Mupirocin (intranasal)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


For use in according to CHQ Management of boils (furunculosis) (MSSA and MRSA decolonisation) OR for Eradication of Staph Aureus nasal colonisation in Cardiac surgery patients



Amber

Mupirocin (topical)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Prevention of peritoneal dialysis catheter exit site infection



Amber

Neomycin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. SAS approval required.




Red

Ofloxacin (eyedrops)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


Use upon advice from ophthalmology team.



Amber

Oseltamivir (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:


For use according to Queensland Infection Clinical Network Guidelines for prescribing oseltamivir for seasonal influenza in 2022



Amber

Piperacillin/Tazobactam (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Posaconazole (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:




Amber

Rifampicin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Chemoprophylaxis of meningococcal contacts on advice from ID consultant (48 hours)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Teicoplanin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Terbinafine (topical)


Approval required:


Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below.



Pre-approved indications:


For use according to QH LAM criteria



Amber

Terbinafine (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications:



  • Upon advice from Dermatologist for microbiologically proven chronic onychomycosis or extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin according to Australian Therapeutic guidelines (Antibiotic) and QH LAM criteria

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Tobramycin (IV/ inhaled/ nebulised)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Cystic fibrosis – as per guideline criteria (IV therapy – up to 14 days, inhaled/nebulised – see guideline)

  • Non CF bronchiectasis (IV – inpatient up to 14 days, HITH - ID approval required)

  • Non CF bronchiectasis (inhaled/nebulised – QCH use endorsed as per guideline; Other sites – as per local ID approval practices)



Amber

Tobramycin (eyedrops and eye ointment)


Approval required:


Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below.



Pre-approved indications:


Upon ophthalmologist advice.



Amber

Trimethoprim/ sulfamethoxazole (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Initial treatment of PJP pneumonia where oral therapy is not tolerated (Up to 48 hours, ID consult and approval for ongoing use required)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.



Amber

Valaciclovir (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Prophylaxis of viral infection for 12 months following allogeneic bone marrow transplant

  • Prophylaxis of viral infection for 3 months following autologous bone marrow transplant.

  • Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours)

  • Herpes zoster in immunocompromised patients (72 hours)

  • Ophthalmic herpes zoster (72 hours)

  • Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.


Amber

ValGANciclovir (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Vancomycin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Amber

Vancomycin (intravitreal or intracameral injection)


Approval required:


Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Upon advice from Ophthalmology for Acute management of Open Globe Injuries  (health.qld.gov.au) (1 dose)



Amber

Voriconazole (intravitreal or intracameral injection)


Approval required:


Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):


Upon advice from Ophthalmology for Acute management of Open Globe Injuries  (health.qld.gov.au) (1 dose)



Amber

Abacavir (oral)



  • ID consult and approval required.

  • For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.



Red

Adefovir (oral)



  • ID consult and approval required.

  • For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.



Red

Amikacin (IV and nebulised)



  • ID consult and approval required.

  • For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.



Red

Amorolfine (topical solution)



  • ID consult and approval required.

  • For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.



Red

Amphotericin B lipid complex (Abelcet) (SAS) (IV)




Red

Amphotericin (Fungizone) (SAS) (IV)




Red

Anidulafungin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Artemeter/lumefantrine (Riamet) (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Artesunate (SAS) (IV)




Red

Atazanavir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Atovaquone (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Atovaquone/ Proguanil (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use




Red

Aztreonam IV and nebulised (SAS)




Red

Bacitracin (topical) (SAS)




Red

Bedaquiline (oral) (SAS)




Red

Benznidazole (oral) (SAS)




Red

Brincidofovir (compassionate access)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use

  • CHQMAC approval required



Red

Capreomycin (IV) (SAS)




Red

Casirivimab/Imdevimab (Ronapreve)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Tixagevimab/Cilgavimab (Evusheld)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Caspofungin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Cefpodoxime (oral) (SAS)




Red

Ceftolozane/tazobactam (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ceftazidime/avibactam (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Chloramphenicol (IV) (SAS)




Red

Chloroquine (SAS)




Red

Cidofovir (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ciprofloxacin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



  • Water immersed wound infection - Prophylaxis for DEEP tissue injury (e.g. bones, joint or tendons) OR Empiric IV treatment of established infection (Up to 24 hours)

  • Penetrating eye injuries/ open globe injuries as per guideline (48 hours)

  • Alternative for immediate severe type hypersensitivity as outlined in CHQ Antibiocard (24 hours)



Red

Clofazimine (oral) (SAS)




Red

Colistin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Clarithromycin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Cycloserine (oral) (SAS)




Red

Daclatasvir (oral) (SAS)




Red

Daptomycin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Darunavir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Delamanid (oral) (SAS)




Red

Dolutegravir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use

  • Compassionate use - CHQMAC approval required



Red

Doripenem (IV) (SAS)




Red

Efavirenz (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Elvitegravir (oral) (as part of FDC product)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Emtricitabine (oral) (as part of FDC product)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Enfuviritide (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Entecavir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ethambutol (oral) (IV – SAS)




Red

Ertapenem (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Erythromycin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ethionamide (oral) (SAS)




3>
Red

Fidaxomicin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Flucytosine (IV/ oral)




Red

Fosfomycin oral and IV (SAS)




Red

Foscarnet (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Fusidic acid (Sodium fusidate) (oral)




Red

Ganciclovir (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Imipenem/cilastatin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Isavuconazole (IV/oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Isoniazid oral and IV (SAS)




Red

Ivermectin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ketoconazole (oral/ shampoo)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Lamivudine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ledipasvir with Sofosbuvir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Letermovir (IV/ oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Levofloxacin (IV/ oral)




Red

Linezolid (IV/ oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Lopinavir/Ritonavir (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Nirmatrelvir/ Ritonavir (Paxlovid) (oral)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Molnupiravir (oral)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Sotrovimab (IV)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Maraviroc (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Mefloquine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Miltefosine (oral) (SAS)




Red

Moxifloxacin (IV/ oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Meropenem/Vaborbactam (IV) (SAS)




Red

Meropenem (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



Red

Methenamine Hippurate (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Micafungin (IV)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):



Amber

Nalidixic acid (PO) (SAS)




Red

Natamycin eyedrops (SAS)




Red

Netilmicin (SAS)




Red

Nevirapine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Niclosamide (oral) (SAS)




Red

Nitazoxanide (oral) (SAS)




Red

Norfloxacin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Palivizumab (IM)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Red

Paromomycin (oral and topical – SAS)




Red

Para-Aminosalicylic acid (SAS)




Red

Pentamidine (IV and nebulised)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Peramivir (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Pivmecillinam (oral) (SAS)




Red

Pentamidine (IV and nebulised)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Polymyxin B (SAS)




Red

Posaconazole (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Praziquantel (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Pretomanid (oral) (SAS)




Red

Primaquine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Pristinamycin (oral) (SAS)




Red

Pylera ( Bismuth, Metronidazole, Tetracycline) (SAS)




Red

Pyrazinamide (oral) (SAS)




Red

Pyrimethamine (oral) (SAS)




Red

Quinine (IV/ oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Quinupristin/Dalfopristin (IV) (SAS)




Red

Raltegravir (oral)




Red

Remdesivir (IV)



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Ribavirin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Rifabutin (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Rifampicin (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Rifapentine (oral) (SAS)




Red

Rifaximin (oral)




Red

Rilpirivine (with tenofovir and emtricitabine) (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Sarilumab



  • ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Sofosbuvir



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Streptomycin (IM) (SAS)




Red

Sulfadiazine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Tafenoquine (oral)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Taurolidine/citrate antiseptic lock (Taurolock)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Tedizolid (SAS)




Red

Telithromycin (SAS)




Red

Tenofovir



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Tetracycline (SAS)




Red

Ticarcillin/clavulanate - Drug discontinued in 2018

Red

Triclosan skin wash



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Tigecycline (IV)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Vancomycin (oral)


Approval required:



Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below.



Pre-approved indications for specific timeframes (for ongoing use, AMS code required):




Red

Voriconazole (IV and eyedrops)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Zanamavir (inhaled)



  • ID consult and approval required.

  • Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use



Red

Zidovudine oral and IV (SAS)




Red